Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Johns Hopkins University said it would eliminate more than 2,000 jobs after the Trump administration rescinded funding for ...

A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...